Introduction
============

There are an estimated 2 million prostate cancer survivors in the US alone.[@b1-clep-5-429] This prevalent survivor pool highlights the need for a better understanding of the long-term health of men with prostate cancer, including their risk of new primary cancers. We therefore conducted a Danish population-based cohort study to examine the risk of new primary cancers in men with prostate cancer compared with that in a matched cohort of men with no history of prostate cancer.[@b2-clep-5-429] We had to resolve several methodological issues to appropriately compare the rates of new primary cancers in men with and without prostate cancer, and this paper focuses on these issues.

First, competing mortality risks can shorten follow-up time faster and more frequently among prostate cancer survivors than in a comparison cohort free of the disease. The clinical course of prostate cancer and survival vary substantially by stage at diagnosis and geographic region. Prostate cancer is frequently diagnosed at an early stage with a favorable prognosis in countries with population-based prostate specific antigen (PSA) screening, such as the US. Accordingly, many men with prostate cancer in the US die with, rather than from, their prostate cancer.[@b3-clep-5-429]--[@b6-clep-5-429] In contrast, in countries without PSA screening, men are diagnosed more often with clinically relevant prostate cancer at a more advanced stage, and a higher proportion die of the disease.[@b7-clep-5-429],[@b8-clep-5-429] Therefore differential competing mortality risks should be addressed when comparing new primary cancer rates in prostate cancer survivors with rates in men without this disease, especially in a country such as Denmark, where the prevalence of PSA screening is low.

Second, men with a history of cancer may have a different diagnostic work-up and treatment regimen compared with men without any previous cancer. Therefore, when studying the rate of new primary cancers in men with and without prostate cancer, steps should be taken to minimize the effects of any potential treatment interference or diagnostic bias.

Third, some men diagnosed with prostate cancer receive a radical prostatectomy (complete removal of the prostate) during the course of their primary treatment and so are no longer at risk for a new primary prostate cancer. In addition, almost 90% of prostate cancers are multi-focal at diagnosis.[@b9-clep-5-429] Therefore, the recognition and coding of a completely separate second primary cancer within the prostate of a man with a history of prostate cancer is unlikely. As prostate cancer accounts for about 14% of all cancers in men globally,[@b10-clep-5-429] men with a history of prostate cancer may appear to have lower rates of any new primary cancer than the background population because they are no longer at risk for prostate cancer itself.

Fourth, multiple comparisons of cancer-specific rates, often within strata of age or clinical variables, can yield false-positive associations.[@b11-clep-5-429] Therefore, analytic methods should be implemented to reduce the potential for spurious, but statistically significant, results.

Finally, an imbalance in risk factors, such as smoking, between cohorts may contribute to differences in rates of new primary cancers between cohorts. However, controlling for these risk factors, particularly when relying on registries as a data source, can be beyond the scope of most studies.

This paper focuses on the methods and rationale used to address some of these issues in our comparison of rates of new primary cancers in a matched cohort study of Danish men with and without prostate cancer.

Methods
=======

Study population
----------------

We conducted this cohort study among men aged ≥15 years old in Denmark. All health-related services in Denmark are recorded for individual patients using their civil personal registration (CPR) number -- a unique identifier encoding sex and date of birth assigned to all Danish residents since 1968. We used the CPR number to link data on an individual level from the Danish Cancer Registry (DCR), Danish National Registry of Patients (DNRP) (covering all Danish hospitals), and the Danish Civil Registration System (CRS).[@b12-clep-5-429]--[@b14-clep-5-429]

### Prostate cancer cohort

The DCR[@b15-clep-5-429] allowed us to identify all men diagnosed with incident prostate cancer (ICD-10 code C61) between January 1, 1978 and December 31, 2003. We excluded men with a history of cancer before their prostate cancer diagnosis (n=3,983). We also excluded men diagnosed with any new primary cancer in the first 4 months after diagnosis (n=600).

### Matched comparison cohort

We used the CRS to assemble a matched comparison cohort.[@b12-clep-5-429] For each prostate cancer patient, we selected a pool of men from the general population who had similar age (matched ±2 years), county of residence, and no history of any cancer on the index date (date of diagnosis for the corresponding prostate cancer patient). We randomly selected five men per prostate cancer patient from this pool of matched men. We terminated follow-up of members of the comparison cohort when they were diagnosed with prostate cancer (n=699); at which point they joined the prostate cancer cohort. As for the prostate cancer cohort, we excluded any men diagnosed with cancer in the first 4 months after the index date. We also terminated follow-up of members of the comparison cohort upon the death or censorship of their matched prostate cancer patient.

Other study variables
---------------------

We obtained information on any potentially confounding comorbid diseases from the DNRP (since 1977). These included alcoholism, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease, and obesity. We also computed the Charlson comorbidity score on the prostate cancer diagnosis date for prostate cancer patients and on the index date for the comparison cohort members.[@b16-clep-5-429] Cancer was completely removed from the Charlson comorbidity index (including prostate cancer for the prostate cancer cohort).

The DCR and CRS provided information on patient demographics. We also used the DCR to retrieve information on disease characteristics for the members of the prostate cancer cohort (cancer stage and initial treatment of prostate cancer). We stratified patients based on the following calendar periods: 1978--1984; 1985--1996; and 1997--2006. These time periods were selected based on important changes that occurred in prostate cancer treatment in Denmark over time.[@b7-clep-5-429],[@b17-clep-5-429]

Study outcomes
--------------

Men were followed from 4 months after their prostate cancer diagnosis/index date until the date of diagnosis of a subsequent cancer and follow-up continued until the date of death, emigration, or 31 December 2006, whichever occurred first, or, for members of the comparison cohort, until censoring or prostate cancer diagnosis. We chose this 4 month cut-off point as the DCR only records cancer-directed treatment up to 4 months after cancer diagnosis date. Ideally we would have started follow-up on the date of completion of prostate cancer treatment.

Statistical analyses
--------------------

### Competing mortality risks and person-time

To examine the impact of the higher death rate in the prostate cancer cohort and the consequently older average age and greater person-time of men in the comparison cohort, we graphed cumulative person-years in both cohorts (dividing by 5 to account for the 5:1 matching of the comparison cohort). We plotted these curves with and without terminating or censoring follow-up of persons in the comparison cohort on the date that their matched prostate cancer patient died or was censored, respectively. Based on these analyses, we chose to terminate members of the comparison cohort from all further analysis when their matched prostate cancer patient died or censor their follow-up on the date their matched prostate cancer patient was censored.

### Diagnostic bias

To remove any potential effect of treatment interference or diagnostic bias, we excluded men with a history of cancer from both cohorts.

### Immunity from prostate cancer

We graphed the rate of all cancers, calculated in overlapping 4 month windows of follow-up, to examine changes in the approximate cancer hazard in both cohorts over time. We graphed this rate with and without counting cases of prostate cancer in the comparison cohort, to assess whether the difference in rates of new primary cancer was attributable to the impact of "immunity" from incident prostate cancer in the prostate cancer cohort.

### Multiple comparisons

We used Cox proportional hazards regression to estimate hazard ratios (HRs) as a measure of the relative risk (RR) of new primary cancers among prostate cancer patients and among men in the comparison cohort, adjusting for comorbidity. We used empirical Bayes methods to adjust for multiple comparisons in the analyses. Empirical Bayes adjustment shrinks individual associations toward the mean of a larger population of associations, in proportion to the ratios of individual variances to the population variance, thereby bringing values with relatively higher variances more toward the central tendency.[@b18-clep-5-429] We report comparisons with and without empirical Bayes shrinkage. All statistical analyses were carried out using SAS 9.13 (SAS Institute Inc., Cary, NC, USA).

Results
=======

[Table 1](#t1-clep-5-429){ref-type="table"} shows descriptive characteristics of the study population, including patient-, clinical-, and treatment-related factors.

Competing mortality risk: person-time in the prostate cancer cohort and comparison cohort
-----------------------------------------------------------------------------------------

[Figure 1A](#f1-clep-5-429){ref-type="fig"} illustrates the cumulative person-time in the prostate cancer and comparison cohorts without terminating or censoring follow-up of men in the comparison cohort at the time of the matched prostate cancer member's death or loss to follow-up, respectively. Cumulative person-time was similar in both cohorts for the first 18 months of follow-up. Subsequently, cumulative person-time was much lower in the prostate cancer cohort, leveling off within approximately 10 years. In contrast, person-time in the comparison cohort continued to increase up to approximately 15 years after the index date before plateauing.

[Figure 1B](#f1-clep-5-429){ref-type="fig"} shows person-time in both cohorts with terminating or censoring follow-up of comparison cohort members at the time of the matched prostate cancer member's death or loss to follow-up, respectively. Person-time was similar for both cohorts during the first 30 months of follow-up. Subsequently, person-time in the comparison cohort was somewhat lower than person-time in the prostate cancer cohort because of terminating or censoring follow-up of the matched persons in the comparison cohort when a man with prostate cancer died or was lost to follow-up. We did not censor follow-up of members of the prostate cancer cohort when a matched person in the comparison cohort died, which explains the small difference in cumulative person-time.

Diagnostic bias
---------------

[Figure 2](#f2-clep-5-429){ref-type="fig"} shows the cumulative incidence of new primary cancers in both cohorts excluding men with a history of other cancers. We note that the decreased incidence of new primary cancers in the prostate cancer cohort only persisted for the first 8 to 10 years of follow-up, at which point incidence became higher in the comparison cohort.

"Immunity" from prostate cancer: hazard of new primary cancer in the prostate cancer and comparison cohorts
-----------------------------------------------------------------------------------------------------------

[Figure 3A](#f3-clep-5-429){ref-type="fig"} shows the approximate hazard of any new primary cancer, including prostate cancer, in the prostate cancer and comparison cohorts, calculated in sliding and overlapping 4 month windows. [Figure 3B](#f3-clep-5-429){ref-type="fig"} shows the rate of new primary cancers in both cohorts excluding prostate cancer as an outcome. For the first four years of follow-up, the rate of new primary cancer was lower in the prostate cancer cohort than in the comparison cohort. Subsequently, there was little difference in the rates of new primaries between the two cohorts.

Multiple comparisons: empirical Bayes shrinkage methods
-------------------------------------------------------

[Table 2](#t2-clep-5-429){ref-type="table"} and [Figure 4](#f4-clep-5-429){ref-type="fig"} show the HR for new primary cancer in the prostate cancer and comparison cohorts by cancer site, with and without empirical Bayes shrinkage. Shrinkage resulted in a change in the rank order of one cancer site (brain cancer, for which the HR changed from 0.47 to 0.72). As indicated in [Figure 4](#f4-clep-5-429){ref-type="fig"}, there was otherwise little change in the HR estimates between using each of the methods.

Discussion
==========

Overall, our analyses found a lower rate of new primary cancers in a cohort of men with prostate cancer compared with a matched cohort of men without prostate cancer. These findings are consistent with a monograph from the US National Cancer Institute, which used Surveillance Epidemiology and End Results (SEER) cancer registry data to describe and quantify the risk of new malignancies among approximately 300,000 prostate cancer survivors in the US.[@b19-clep-5-429] However in the current manuscript, we extend this previous research by focusing on epidemiological methods we used to overcome the non-equivalent person-time in the two cohorts, treatment interference/diagnostic bias, prostate cancer "immunity" among men with prostate cancer, and potential multiple comparisons.

The SEER study reported a standardized incidence rate (SIR) of any new primary cancer including and excluding prostate cancer as an outcome (SIR =0.60, and SIR =0.90, respectively). Accordingly, we graphed the approximate hazard with and without prostate cancer as an outcome. Excluding prostate cancer as an outcome reduced the difference in the rate of new primary cancers in the two cohorts, and the lower rate in the prostate cancer cohort persisted only during the first 5 years after prostate cancer diagnosis/index date. These graphs agree with the SEER study findings and suggest that new primary prostate cancers in the comparison cohort may have contributed to the overall deficit of new primary cancers among men with prostate cancer. This deficit is expected, as some men with prostate cancer are treated with radical prostatectomy and therefore are no longer at risk of the disease. In addition, due to the multifocal nature of prostate cancer, a new primary cancer in the prostate may be unlikely to be regarded as a separate cancer to the original prostate cancer.

As the cancer hazard increases with age, the lower rate of new primary cancers among men with prostate cancer may be attributable to less person-time at risk than men without the disease. Evidence of the tendency toward such noncomparability as follow-up time increases comes from our initial analyses (without censoring of the comparison cohort at the time of the matched prostate cancer patient's death or loss to follow-up), which demonstrated that the initial 5:1 ratio of men matched to prostate cancer patients yielded a 10:1 ratio in person-years by the end of follow-up (data not presented), despite baseline matching on age. This difference resulted from a much higher death rate in the prostate cancer cohort and a progressively older age distribution among men in the comparison cohort. We illustrated this imbalance in person-time between the two cohorts by graphing the cumulative person-time with and without terminating or censoring follow-up of members of the comparison cohort when the corresponding prostate cancer patient died or was lost to follow-up. Based on these graphs, in all subsequent analyses we terminated or censored follow-up of men in the comparison cohort upon the death or loss to follow-up of the corresponding prostate cancer patient. This method allowed us to preserve the age matching and substantially reduced any residual confounding due to age.

The difference in the rate of new primary cancers among men with and without prostate cancer reported in the SEER study lies closer to the null than the difference we observed in this Danish population (0.90, 95% CI =0.89, 0.91 in the SEER study vs 0.84, 95% CI =0.80, 0.88 in our study). There are some plausible reasons for this. First, in our study, terminating or censoring the person-time of the comparison cohort is equivalent to calculating a SIR, as used by SEER.[@b19-clep-5-429] A prototypical SIR uses the person-time of the exposed cohort (prostate cancer cohort) and the outcome rates of the unexposed cohort (comparison cohort).[@b20-clep-5-429] In many SIR calculations, including that in the SEER study,[@b19-clep-5-429] these comparative rates are obtained as age-, sex-, and calendar-specific rates. However, these comparative rates are often based on the whole population, which includes prostate cancer survivors. Since prostate cancer survivors are not rare, the comparison is between a part and the whole, rather than a comparison of two distinct parts (prostate cancer survivors compared with men without a history of prostate cancer). Our design retained the person-time comparability of the SIR method, with the advantage of calculating rates for two non-overlapping populations. Second, although PSA screening has increased on an opportunistic basis in Denmark over the past decade,[@b21-clep-5-429] more prevalent PSA screening in the US is likely to contribute to longer average prostate cancer survival in the US compared with Denmark.[@b22-clep-5-429] In the US, prostate cancer is somewhat over-diagnosed (PSA screening can uncover clinically irrelevant tumors or benign abnormalities) and represents a mix of aggressive disease with poor survival and relatively latent disease with long survival and a low potential for metastasis.[@b23-clep-5-429] If only more aggressive prostate cancer diagnoses are markers of reduced risk for subsequent cancers, then the difference between rates of new primary cancer in prostate cancer patients and men free of this disease in the US population would be diluted given the case mix. This mixing would bias the SEER result towards the null compared with the result in our largely unscreened Danish population.

Removal of prostate cancer as an outcome in both cohorts had a slight effect on the hazard rate of new primary cancers in the two cohorts. This suggests that prostate cancer immunity contributed slightly to the deficit rate of new primary cancers in the prostate cancer cohort.

In studies such as ours, with multiple cancer outcomes, it is important to consider the issue of multiple comparisons, which can lead to undue attention to spurious associations. Consistent with Greenland's guidelines, we used empirical Bayes shrinkage methods to address the problem.[@b18-clep-5-429] The empirical Bayes method reduces the potential for false positive results due to multiple comparisons. With the exception of one cancer site (brain), our findings show similar associations and rankings with and without empirical Bayes adjustment. This insensitivity to adjustment probably stems from large numbers of nearly all cancers in both the prostate cancer cohort and the matched comparison cohort.

Despite our best efforts to address the issues of competing mortality risks, diagnostic bias, prostate cancer immunity, and multiple comparisons, our study showed a substantial difference in the rates of new primary cancer in a cohort of men with and without prostate cancer. This may be a real effect or may be reflective of factors beyond our methodological control. We were unable to assess the influence of cancer-related risk factors, which may have been imbalanced between the two cohorts. For example, men with prostate cancer who smoke are said to have a worse prognosis than non-smokers. We did note a higher rate of chronic obstructive pulmonary disease in the prostate cancer cohort, and accordingly, a higher rate of smoking-related cancers in the comparison cohort.[@b2-clep-5-429] This suggests that the true difference in the rate of new primary cancers between the two cohorts is likely to be even smaller than what resulted from our methodological approaches.
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![(**A**) Cumulative person-time (per 10,000 years) in the prostate cancer cohort and the comparison cohort (adjusted for 5:1 matching). (**B**) Cumulative person-time (per 10,000 years) in the prostate cancer cohort and the comparison cohort, with censoring of matched persons in the comparison cohort at the time of the prostate cancer patient's death.](clep-5-429Fig1){#f1-clep-5-429}

![Cumulative incidence of new primary cancers in the prostate cancer cohort (n=30,220) and the comparison cohort (n=151,100) (excluding men with a history of other cancers) with terminating or censoring follow-up of the comparison cohort at the death or loss to follow-up of their index man with prostate cancer.](clep-5-429Fig2){#f2-clep-5-429}

![(**A**) Rate of new primary cancers in the prostate cancer cohort and comparison cohort, calculated within sliding and overlapping 4 month windows, excluding men with a history of cancer, and including prostate cancer as an outcome. (**B**) Rate of new primary cancers in the prostate cancer cohort and comparison cohort, calculated within sliding and overlapping 4 month windows, excluding men with a history of cancer, and excluding prostate cancer as an outcome.](clep-5-429Fig3){#f3-clep-5-429}

![Hazard ratios of new primary malignancies in the prostate cancer cohort vs the comparison cohort with and without empirical Bayes shrinkage.\
**Note:** Prostate cancer, basal cell carcinoma, and in situ breast carcinoma are omitted as outcomes.\
**Abbreviation:** CI, confidence interval.](clep-5-429Fig4){#f4-clep-5-429}

###### 

Descriptive characteristics of the prostate cancer cohort (n=30,220) and comparison cohort (n=151,100) -- excluding men with a history of cancer from both cohorts

  Variable                                                         Prostate cancer patients   Comparison cohort             
  ---------------------------------------------------------------- -------------------------- ------------------- --------- -------
  Overall                                                          30,220                     100.0               151,100   100.0
  Calendar period                                                                                                           
   1978--1984                                                      6,488                      21.5                32,440    21.5
   1985--1996                                                      13,100                     43.3                65,500    43.3
   1997--2003                                                      10,632                     35.2                53,160    35.2
  Age at prostate cancer diagnosis/index date                                                                               
   0--59 years                                                     2,074                      6.9                 10,988    7.3
   60--69 years                                                    8,252                      27.3                41,481    27.5
   70--79 years                                                    13,376                     44.3                66,744    44.2
   80+ years                                                       6,518                      21.6                31,887    21.1
  Charlson comorbidity index score                                                                                          
   0                                                               22,284                     73.7                111,413   73.7
   1--2                                                            6,915                      22.9                34,691    23.0
   3+                                                              1,021                      3.4                 4,996     3.3
  Tumor stage[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                                     
   Localized                                                       12,950                     42.9                          
   Regional                                                        2,051                      6.8                           
   Distant                                                         7,814                      25.9                          
   Unspecified                                                     7,405                      24.5                          
  Chemotherapy[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                                    
   No                                                              29,954                     99.1                          
   Yes                                                             266                        0.9                           
  Radiotherapy[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                                    
   No                                                              28,682                     94.9                          
   Yes                                                             1,538                      5.1                           
  Surgery[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                                         
   No                                                              11,290                     37.4                          
   Yes                                                             18,930                     62.6                          
  Anti hormone therapy[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                            
   No                                                              24,931                     82.5                          
   Yes                                                             5,289                      17.5                          
  None or symptomatic[†](#tfn1-clep-5-429){ref-type="table-fn"}                                                             
   No                                                              25,792                     85.3                          
   Yes                                                             4,428                      14.7                          

**Note:**

These variables did not apply to men in the comparison cohort, so they were put in the same category as their matched member of the prostate cancer cohort. None or symptomatic refers to no treatment or treatment on appearance of symptoms.

###### 

Hazard ratio (HR) of a new primary cancer in the prostate cancer cohort vs the comparison cohort, by cancer site. HR with and without empirical Bayes (EB) adjustments for 27 cancer sites, with lower and upper confidence limits (CL)

  Cancer site                                No EB adjustments   EB adjustments                        
  ------------------------------------------ ------------------- ---------------- ------ ------ ------ ------
  Lower gastrointestinal cancers             0.92                0.82             1.02   0.90   0.74   1.11
  Urinary system                             0.85                0.71             1.02   0.84   0.67   1.06
  Upper gastrointestinal tract               0.77                0.63             0.94   0.78   0.61   0.99
  Lungs and respiratory system               0.60                0.53             0.68   0.63   0.51   0.77
  Liver/alcohol-related cancers              0.80                0.64             1.01   0.81   0.63   1.04
  Malignant neoplasms of ill-defined sites   0.65                0.53             0.80   0.69   0.54   0.89
  Brain                                      0.47                0.26             0.86   0.72   0.52   1.00
  Skin                                       1.02                0.93             1.11   1.00   0.83   1.22
  Kidney and renal pelvis                    1.13                0.87             1.48   0.99   0.76   1.29
  Pancreas                                   0.75                0.57             0.97   0.77   0.59   1.01
  Leukemia                                   0.85                0.66             1.09   0.84   0.64   1.09
  Other and unspecified cancers              0.89                0.73             1.08   0.87   0.68   1.10
